Verastem, Inc.

Verastem, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for cancer. Its business centers on oncology drug candidates and approved products, with development, manufacturing, and commercialization activities conducted through third-party partners.

−550,2 %

−677,6 %

+209,1 %

3.09

3.07

— Verastem, Inc.
%
Commercial oncology therapy55% Approved cancer treatment sold in the U.S. for a specific oncology indication.
Clinical-stage product candidates35% Drug candidates in development for additional oncology indications and future approvals.
Regulatory and commercialization activities10% Activities tied to approval, launch, market access, and post-approval support.

Verastem’s direct customers are healthcare providers, hospitals, oncology practices, and specialty pharmacies that...

  • Oncology prescribersprimary

    Oncologists and cancer centers that prescribe AVMAPKI FAKZYNJA CO-PACK for eligible patients.

  • Specialty pharmaciesprimary

    Dispense the product and manage patient access, fulfillment, and distribution.

  • Government and commercial payorsprimary

    Medicaid, 340B, VA/FSS, and private payors that determine reimbursement and net access.

  • Clinical research sitessecondary

    Hospitals, investigators, and CRO-supported sites that run trials for pipeline candidates.

Verastem is headquartered in the United States and its commercial focus is primarily the U.S. market...

  • •Headquartered in the United States
  • •Primary commercial market is the U.S.
  • •Subject to U.S. federal and state pricing programs
  • •Foreign pricing controls can affect future international launches

Verastem’s strategy is centered on building a commercial oncology franchise around AVMAPKI FAKZYNJA CO-PACK while...

01
Commercialize AVMAPKI FAKZYNJA CO-PACKshort-term

The company’s near-term business depends heavily on uptake of its approved oncology product.

02
Advance clinical pipelinemedium-term

Additional approvals are needed to diversify the product base and extend the franchise.

03
Strengthen supply and manufacturing reliabilitymedium-term

Third-party manufacturing is essential to both commercial supply and clinical development.

Verastem is exposed to concentration risk because its business depends heavily on the commercial success of a single...

high

Dependence on AVMAPKI FAKZYNJA CO-PACK

A large share of the company’s commercial prospects depends on one approved oncology product.

Scope
U.S. commercial sales
Materiality
high
high

Clinical development failure

Pipeline candidates may not show sufficient efficacy or safety to gain approval.

Scope
Product candidates in development
Materiality
high
high

Third-party manufacturing dependence

The company has no manufacturing facilities and relies on external suppliers for supply.

Scope
Commercial and clinical supply
Materiality
high
high

Financing and debt servicing risk

Debt obligations and potential acceleration could constrain operations and development spending.

Scope
Note Purchase Agreement and related indebtedness
Materiality
high
medium

Reimbursement and pricing pressure

Coverage, rebates, and government pricing programs can reduce net revenue and access.

Scope
Medicaid, 340B, VA/FSS, private payors
Materiality
high
medium

Regulatory and advertising enforcement

FDA and other agencies can impose requirements, warnings, or launch restrictions.

Scope
Commercial promotion and labeling
Materiality
medium
Revenue recognition and gross-to-net deductions
Net product revenue
Government pricing programs
Accrued rebates and revenue reserves
Product return and rebate reserves
Revenue and liabilities
Debt and revenue participation accounting
Interest expense, liabilities, and net revenue

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

Immunome Inc.

IMNM · Pharmaceutical Preparations

Cogent Biosciences, Inc.

COGT · Pharmaceutical Preparations

Upstream Bio, Inc.

UPB · Pharmaceutical Preparations

VERACYTE, INC.

VCYT · Services-Medical Laboratories

VERU INC.

VERU · Pharmaceutical Preparations

: 29/04/2026